Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study

Kaibullayeva, Jamilya; Ualiyeva, Aliya; Oshibayeva, Ainash; Dushpanova, Anar; Marshall, John K.

doi:10.5217/ir.2019.00099

“…Crohn's disease (CD) was previously known as a disease that primarily affects people from the Western hemisphere, but its incidence is rapidly increasing in Asia alongside the ever-increasing adoption of Western lifestyle and cultural influences on the continent. [1][2][3] According to the Songpa-Kangdong inflammatory bowel disease (SK-IBD) study, which investigated a well-defined populationbased IBD patient cohort from the Songpa-Kangdong district of Seoul, Korea, the mean annual incidence of CD has increased from 0.06/100,000 during 1986 and 1990 to 2.44/100,000 during 2011 and 2015. 4 However, both the genotypic and phenotypic characteristics of CD in Asians are known to be different from those in Westerners in many aspects.…”

Section: Introductionmentioning

confidence: 99%

Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study

Ye

¹

,

Hong

²

,

Seo

³

et al. 2022

View full text Add to dashboard Cite

Background/Aims: The long-term course of Crohn's disease (CD) has never been evaluated in non-Caucasian population-based cohorts. The aim of the present study was to evaluate the longterm prognosis of Korean CD patients in the well-defined population-based Songpa-Kangdong inflammatory bowel disease cohort. Methods:Outcomes of disease and their predictors were evaluated for 418 patients diagnosed with CD between 1986 and 2015.Results: During a median of 123 months, systemic corticosteroids, thiopurines, and anti-tumor necrosis factor (TNF) agents were administered to 58.6%, 81.3%, and 37.1% of patients, respectively. Over time, the cumulative probability of starting corticosteroids significantly decreased (p=0.001), whereas that of starting thiopurines and anti-TNFs significantly increased (both p<0.001). The cumulative probability of behavioral progression was 54.5% at 20 years, and it significantly decreased during the anti-TNF era. Intestinal resection was required for 113 patients (27.0%). The cumulative probabilities of intestinal resection at 1, 5, 10, 20, and 25 years after CD diagnosis were 12.7%, 16.5%, 23.8%, 45.1%, and 51.2%, respectively. Multivariable Cox regression analysis identified stricturing behavior at diagnosis (adjusted hazard ratio [aHR], 2.70; 95% confidence interval [CI], 1.55 to 4.71), penetrating behavior at diagnosis (aHR, 11.15; 95% CI, 6.91 to 17.97), and diagnosis of CD during the anti-TNF era (aHR, 0.51; 95% CI, 0.35 to 0.76) as independently associated with intestinal resection. The standardized mortality ratio among CD patients was 1.36 (95% CI, 0.59 to 2.68). Conclusions:The long-term prognosis of Korean patients with CD is at least as good as that of Western CD patients, as indicated by the low intestinal resection rate. Moreover, behavioral progression and intestinal resection rates have decreased over the past 3 decades.

show abstract

“…The incidence of both Crohn's disease (CD) and ulcerative colitis is increasing in Korea and other Asian countries, [1][2][3] along with the usage of anti-tumor necrosis factor α (TNF-α) agents such as infliximab and adalimumab, which can induce remission or maintain stable disease activity in patients with inflammatory bowel disease (IBD). [4][5][6] Hepatitis B virus (HBV) infection is endemic among the general population in East Asia, unlike in Western countries.…”

Section: Introductionmentioning

confidence: 99%

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease

Lee

¹

,

Wei

²

,

Lee

³

et al. 2022

View full text Add to dashboard Cite

Background/Aims: Little is known about the clinical course of hepatitis B virus (HBV)-infected patients undergoing anti-tumor necrosis factor α (TNF-α) therapy for inflammatory bowel disease (IBD). We aimed to investigate the clinical course of HBV infection and IBD and to analyze liver dysfunction risks in patients undergoing anti-TNF-α therapy.Methods: This retrospective multinational study involved multiple centers in Korea, China, Taiwan, and Japan. We enrolled IBD patients with chronic or resolved HBV infection, who received anti-TNF-α therapy. The patients' medical records were reviewed, and data were collected using a web-based case report form.Results: Overall, 191 patients (77 ulcerative colitis and 114 Crohn's disease) were included, 28.3% of whom received prophylactic antivirals. During a median follow-up duration of 32.4 months, 7.3% of patients experienced liver dysfunction due to HBV reactivation. Among patients with chronic HBV infection, the proportion experiencing liver dysfunction was significantly higher in the non-prophylaxis group (26% vs 8%, p=0.02). Liver dysfunction occurred in one patient with resolved HBV infection. Antiviral prophylaxis was independently associated with an 84% reduction in liver dysfunction risk in patients with chronic HBV infection (odds ratio, 0.16; 95% confidence interval, 0.04 to 0.66; p=0.01). The clinical course of IBD was not associated with liver dysfunction or the administration of antiviral prophylaxis.Conclusions: Liver dysfunction due to HBV reactivation can occur in HBV-infected IBD patients treated with anti-TNF-α agents. Careful monitoring is needed in these patients, and antivirals should be administered, especially to those with chronic HBV infection.

show abstract

“…Inflammatory bowel disease (IBD) includes a group of diseases featuring recurring and persistent chronic inflammation of the intestine, such as Crohn's disease (CD) and ulcerative colitis (UC). These are chronic, debilitating disorders that require lifelong medical treatment and even surgery [ 1 , 2 ]. The pathogenesis of IBD is not fully understood but is thought to be multifactorial, involving variations in the patient's genome and environmental factors and alterations in the intestinal microbiota and mucosal immune response [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity

Kim

¹

,

Lee

²

,

Kim

³

et al. 2021

Canadian Journal of Gastroenterology and Hepatology

View full text Add to dashboard Cite

Background and Aim. The prevalence of obesity is increasing globally as is the prevalence of inflammatory bowel disease (IBD). Herein, we sought to evaluate the characteristics and prognosis of IBD in patients with obesity. Methods. We retrospectively reviewed the medical records of IBD patients who visited Asan Medical center. We used a large, well-characterized referral center-based cohort. The clinical features of IBD patients with body mass index (BMI) over 30 and matched controls with BMI under 30 were compared. Results. Among the 6,803 IBD patients enrolled in the Asan IBD Registry between June 1989 and December 2016, we identified 16 patients with Crohn’s disease (CD) and 27 patients with ulcerative colitis (UC) whose BMI was over 30 at the time of diagnosis. Their clinical characteristics and course were compared with those of 64 and 108 matched patients with CD and UC, respectively. There were no significant differences in the risk of using steroids (hazards ratio (HR) = 0.633 and P = 0.254 ), immunomodulators (HR = 0.831 and P = 0.517 ), and anti-tumor necrosis factor (TNF) therapy (HR = 1.539 and P = 0.351 ) and risk of bowel resections (HR = 1.858 and P = 0.231 ) between CD patients with BMI over 30 and those with BMI under 30; similarly, UC patients did not show significant differences in the risk of using steroids (HR = 0.613 and P = 0.145 ), immunomodulators (HR = 0.492 and P = 0.111 ), anti-TNF therapy (HR = 0.385 and P = 0.095 ), and risk of colectomy (HR = 0.262 and P = 0.104 ). In the subgroup analysis, under-weight UC patients had a higher cumulative probability of needing steroids (HR = 0.2510 and P = 0.042 ), needing immunomodulators (HR = 0.097 and P = 0.014 ), and a higher risk of receiving colectomy (HR = 0.024 and P = 0.019 ) than obese UC patients. Conclusions. Obese IBD patients with CD or UC did not show significantly different clinical features from nonobese IBD patients.

show abstract

Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study

Cited by 33 publications

References 32 publications

Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study

Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study

Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease

The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity

Contact Info

Product

Resources

About